Kirschbaum Mark 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Feb 2, 2023
Insider Transaction Report
Form 4
Kirschbaum Mark
Chief Medical Officer
Transactions
- Award
Common Stock
2023-01-31+31,200→ 31,200 total
Footnotes (1)
- [F1]The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.